[
  {
    "ts": null,
    "headline": "Trump administration not backing down on Big Pharma pressure campaign",
    "summary": "The pharmaceutical industry's patience is wearing thin with the Trump administration's pressure. But the administration doesn't care.",
    "url": "https://finnhub.io/api/news?id=76fcd69c6045725b019f23ad0b4cec795c0cd81ef0f8a8bb1e378c46cad73ebf",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1747488631,
      "headline": "Trump administration not backing down on Big Pharma pressure campaign",
      "id": 134567759,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "The pharmaceutical industry's patience is wearing thin with the Trump administration's pressure. But the administration doesn't care.",
      "url": "https://finnhub.io/api/news?id=76fcd69c6045725b019f23ad0b4cec795c0cd81ef0f8a8bb1e378c46cad73ebf"
    }
  },
  {
    "ts": null,
    "headline": "3 Magnificent Stocks That Are Passive Income Machines",
    "summary": "Abbott Laboratories is a dividend stock you can buy and (almost) forget about.  AbbVie has proved its resilience by becoming stronger after losing patent exclusivity for its blockbuster drug Humira.  Johnson & Johnson is a seasoned dividend payer for all seasons.",
    "url": "https://finnhub.io/api/news?id=a040f4e761ae40d6ce5e84654b3744c425334484bb6dde50fe85073579531fa7",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1747478400,
      "headline": "3 Magnificent Stocks That Are Passive Income Machines",
      "id": 134567797,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Abbott Laboratories is a dividend stock you can buy and (almost) forget about.  AbbVie has proved its resilience by becoming stronger after losing patent exclusivity for its blockbuster drug Humira.  Johnson & Johnson is a seasoned dividend payer for all seasons.",
      "url": "https://finnhub.io/api/news?id=a040f4e761ae40d6ce5e84654b3744c425334484bb6dde50fe85073579531fa7"
    }
  },
  {
    "ts": null,
    "headline": "Dividend Champion, Contender, And Challenger Highlights: Week Of May 18",
    "summary": "Discover weekly dividend updates for Dividend Champions, Contenders, and Challengers, including changes, ex-dividend dates, and upcoming pay dates.",
    "url": "https://finnhub.io/api/news?id=32a804b3a7c6c825db45e32302d9c503c62d094fe5f0249a1698078935f953a6",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1747446703,
      "headline": "Dividend Champion, Contender, And Challenger Highlights: Week Of May 18",
      "id": 134530944,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1072593728/image_1072593728.jpg?io=getty-c-w1536",
      "related": "JNJ",
      "source": "SeekingAlpha",
      "summary": "Discover weekly dividend updates for Dividend Champions, Contenders, and Challengers, including changes, ex-dividend dates, and upcoming pay dates.",
      "url": "https://finnhub.io/api/news?id=32a804b3a7c6c825db45e32302d9c503c62d094fe5f0249a1698078935f953a6"
    }
  }
]